Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk.
Member count: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Missouri T... | missourite... |